Grifols | GRFS - Net Income


Grifols reported EUR114.37M in Net Income for its fiscal quarter ending in December of 2025.





Net Income Change Date
Alaunos Therapeutics USD -952K 54K Jun/2026
Arca Biopharma USD -31.82M 2.24M Mar/2026
aTyr Pharma USD -134K 19K Jun/2026
Bio Path USD -270K 706K Mar/2026
Brainstorm Cell Therapeutics USD -2.13M 21K Mar/2026
Capricor Therapeutics USD -30.17M 5.6M Dec/2025
Cara Therapeutics USD -6.8M 1.28M Mar/2026
GlaxoSmithKline GBP 1.54B 1.11B Sep/2026
Grifols EUR 114.37M 34.03M Dec/2025
Immunic USD -19.3M 6.28M Dec/2025
Minerva Neurosciences USD 1.44M 21.07M Dec/2024
Nektar Therapeutics USD -44.9M 8.82M Mar/2026
Sangamo BioSciences USD -36.13M 12.96M Jun/2024
TherapeuticsMD USD -1.09M 356K Jun/2024